About Ironwood Pharmaceuticals (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IRWD
- CUSIP: 46333X10
- Web: www.ironwoodpharma.com
- Market Cap: $2.17 billion
- Outstanding Shares: 149,591,000
- 50 Day Moving Avg: $15.86
- 200 Day Moving Avg: $16.79
- 52 Week Range: $12.48 - $19.94
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -25.03
- P/E Growth: -0.25
- Annual Revenue: $270.81 million
- Price / Sales: 8.02
- Book Value: $0.03 per share
- Price / Book: 484.00
- EBITDA: ($84,770,000.00)
- Net Margins: -52.97%
- Return on Equity: -333.83%
- Return on Assets: -18.83%
- Debt-to-Equity Ratio: 79.64%
- Current Ratio: 4.27%
- Quick Ratio: 4.27%
- Average Volume: 1.24 million shs.
- Beta: 1.48
- Short Ratio: 11.15
Frequently Asked Questions for Ironwood Pharmaceuticals (NASDAQ:IRWD)
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. The company had revenue of $65.10 million for the quarter, compared to analysts' expectations of $70 million. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The firm's quarterly revenue was up 19.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.16) EPS. View Ironwood Pharmaceuticals' Earnings History.
When will Ironwood Pharmaceuticals make its next earnings announcement?
Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?
8 analysts have issued 1 year price targets for Ironwood Pharmaceuticals' stock. Their forecasts range from $13.00 to $21.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $18.29 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Ligand Pharmaceuticals Incorporated (LGND), INC Research Holdings (INCR), Portola Pharmaceuticals (PTLA), Blueprint Medicines Corporation (BPMC), SAGE Therapeutics (SAGE), Intrexon Corporation (XON), Spectrum Pharmaceuticals (SPPI), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Genus plc (GNS), Medpace Holdings (MEDP), Immunomedics (IMMU), Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN) and Cellectis S.A. (CLLS).
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Peter M. Hecht Ph.D., Chief Executive Officer, Director
- Thomas Graney, Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
- Mark G. Currie Ph.D., Senior Vice President, Chief Scientific Officer, President - Research and Development
- Thomas A. McCourt, Senior Vice President - Marketing and Sales, Chief Commercial Officer
- Halley E. Gilbert Esq., Senior Vice President, Chief Legal Officer, Secretary
- Christopher I. Wright M.D. Ph.D., Senior Vice President - Global Development and Chief Development Officer
- Terrance G. McGuire, Non-Executive Independent Chairman of the Board
- Andrew Dreyfus, Independent Director
- Marsha H. Fanucci, Independent Director
- Julie H. McHugh, Independent Director
Who owns Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nationwide Fund Advisors (0.19%). Company insiders that own Ironwood Pharmaceuticals stock include Edward P Owens, Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht, Thomas A Mccourt and Thomas Graney. View Institutional Ownership Trends for Ironwood Pharmaceuticals.
Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?
How do I buy Ironwood Pharmaceuticals stock?
Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $14.52.
Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$18.29 (25.93% upside)|Consensus Price Target History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/25/2017||Mizuho||Reiterated Rating||Buy||$23.00 -> $20.00||Medium|
|8/21/2017||Cowen and Company||Set Price Target||Buy||$20.00||Medium|
|7/22/2017||Wells Fargo & Company||Set Price Target||Buy||$19.00||Low|
|7/21/2017||Wood & Company||Downgrade||Overweight -> Neutral||Low|
|7/21/2017||J P Morgan Chase & Co||Reiterated Rating||Overweight -> Neutral||$20.00 -> $19.00||High|
|3/13/2017||BTIG Research||Reiterated Rating||Buy||$18.00 -> $21.00||Low|
|2/22/2017||Barclays PLC||Reiterated Rating||Equal Weight -> Equal Weight||$13.00 -> $16.00||N/A|
|9/27/2016||WallachBeth Capital||Boost Price Target||Hold||$15.00 -> $17.00||N/A|
|8/8/2016||Leerink Swann||Reiterated Rating||Market Perform||$10.00 -> $14.00||N/A|
|4/28/2016||JP Morgan Cazenove||Reiterated Rating||Overweight||$15.00||N/A|
|4/26/2016||Morgan Stanley||Reiterated Rating||Hold||N/A|
|3/21/2016||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Neutral||$14.00||N/A|
Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)Earnings History by Quarter for Ironwood Pharmaceuticals (NASDAQ IRWD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q2 2017||($0.23)||($0.28)||$70.00 million||$65.10 million||View||Listen|
|5/8/2017||Q1 2017||($0.19)||($0.33)||$69.39 million||$52.16 million||View||Listen|
|2/21/2017||Q416||($0.24)||($0.12)||$77.34 million||$87.50 million||View||Listen|
|11/3/2016||Q316||($0.23)||($0.18)||$60.01 million||$66.00 million||View||N/A|
|8/4/2016||Q216||($0.15)||($0.16)||$54.49 million||$54.40 million||View||N/A|
|5/9/2016||Q116||($0.14)||($0.08)||$52.97 million||$66.00 million||View||N/A|
|2/18/2016||Q415||($0.17)||($0.10)||$44.78 million||$53.30 million||View||Listen|
|11/3/2015||Q315||($0.20)||($0.25)||$39.81 million||$39.60 million||View||Listen|
|8/5/2015||Q215||($0.22)||($0.34)||$36.08 million||$27.74 million||View||N/A|
|5/5/2015||Q115||($0.23)||($0.24)||$32.30 million||$28.90 million||View||N/A|
|2/12/2015||Q414||($0.21)||($0.27)||$35.20 million||$38.10 million||View||Listen|
|11/4/2014||Q314||($0.32)||($0.30)||$21.20 million||$16.90 million||View||Listen|
|8/4/2014||Q214||($0.36)||($0.38)||$15.75 million||$6.84 million||View||Listen|
|4/29/2014||Q1||($0.45)||($0.38)||$8.52 million||$14.60 million||View||Listen|
|1/21/2014||Q413||($0.50)||($0.43)||$7.13 million||$5.00 million||View||Listen|
|10/22/2013||Q313||($0.57)||($0.51)||$6.54 million||$4.90 million||View||N/A|
|7/23/2013||Q2 2013||($0.70)||($0.57)||$6.32 million||$9.70 million||View||N/A|
|4/23/2013||Q1 2013||($0.71)||($0.87)||$8.94 million||$3.30 million||View||N/A|
|1/15/2013||Q4 2012||($0.49)||($0.41)||$16.17 million||$27.00 million||View||N/A|
Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)
2017 EPS Consensus Estimate: ($0.75)
2018 EPS Consensus Estimate: ($0.45)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Ownership Percentage: 7.63%Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership Percentage: 97.16%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/5/2017||Julie Mchugh||Director||Sell||1,500||$16.16||$24,240.00|| |
|8/18/2017||Gina Consylman||Insider||Sell||207||$14.34||$2,968.38|| |
|6/22/2017||Halley E Gilbert||Insider||Sell||35,000||$19.75||$691,250.00|| |
|5/15/2017||Thomas A Mccourt||Insider||Sell||30,000||$18.20||$546,000.00|| |
|2/14/2017||Halley E Gilbert||Insider||Sell||37,385||$16.75||$626,198.75|| |
|1/12/2017||Peter M Hecht||CEO||Sell||65,987||$15.67||$1,034,016.29|| |
|12/5/2016||Lawrence S Olanoff||Director||Sell||3,200||$15.68||$50,176.00|| |
|9/6/2016||Lawrence S Olanoff||Director||Sell||3,200||$13.72||$43,904.00|| |
|8/19/2016||Gina Consylman||Insider||Sell||207||$13.54||$2,802.78|| |
|6/3/2016||Lawrence S Olanoff||Director||Sell||2,200||$12.92||$28,424.00|| |
|5/25/2016||Halley E Gilbert||Insider||Sell||20,275||$12.19||$247,152.25|| |
|3/11/2016||Peter M Hecht||CEO||Sell||120,000||$10.72||$1,286,400.00|| |
|3/7/2016||Lawrence S Olanoff||Director||Sell||2,200||$11.11||$24,442.00|| |
|2/24/2016||Edward P Owens||Director||Buy||10,000||$8.32||$83,200.00|| |
|2/24/2016||Gina Consylman||CAO||Sell||420||$8.50||$3,570.00|| |
|2/24/2016||Mark G Currie||Insider||Sell||152,154||$8.53||$1,297,873.62|| |
|2/24/2016||Thomas Graney||CFO||Sell||563||$8.50||$4,785.50|| |
|12/15/2015||Peter M. Hecht||CEO||Sell||73,418||$11.07||$812,737.26|| |
|12/7/2015||Lawrence S Olanoff||Director||Sell||2,200||$11.77||$25,894.00|| |
|9/4/2015||Lawrence S Olanoff||Director||Sell||3,725||$10.97||$40,863.25|| |
|3/17/2015||Peter M Hecht||CEO||Sell||200,000||$15.62||$3,124,000.00|| |
|3/12/2015||Joseph C Cook Jr||Director||Sell||5,883||$15.54||$91,421.82|| |
|3/10/2015||Bryan E Roberts||Director||Sell||95,998||$15.20||$1,459,169.60|| |
|3/3/2015||Peter M Hecht||CEO||Sell||63,442||$15.75||$999,211.50|| |
|2/20/2015||Joseph C Cook Jr||Director||Sell||35,500||$15.60||$553,800.00|| |
|12/15/2014||Bryan E Roberts||Director||Sell||19,792||$15.20||$300,838.40|| |
|6/12/2014||Bryan E Roberts||Director||Sell||200,000||$14.24||$2,848,000.00|| |
|5/29/2014||Michael J Higgins||COO||Sell||50,000||$14.56||$728,000.00|| |
|5/22/2014||Mark Currie||Insider||Sell||25,000||$13.93||$348,250.00|| |
|4/24/2014||Mark Currie||Insider||Sell||25,000||$11.67||$291,750.00|| |
|1/23/2014||Mark Currie||Insider||Sell||20,000||$14.38||$287,600.00|| |
|1/14/2014||Bryan Roberts||Director||Sell||21,200||$12.57||$266,484.00|| |
|1/13/2014||Bryan Roberts||Director||Sell||823,350||$12.71||$10,464,778.50|| |
|1/6/2014||Bryan Roberts||Director||Sell||55,450||$12.01||$665,954.50|| |
|11/7/2013||Terrance Mcguire||Director||Sell||2,083||$9.11||$18,976.13|| |
|6/17/2013||Michael J Higgins||COO||Sell||150,000||$11.74||$1,761,000.00|| |
|3/11/2013||Thomas A Mccourt||Insider||Sell||40,000||$17.00||$680,000.00|| |
|11/5/2012||Peter M Hecht||CEO||Buy||50,000||$11.65||$582,500.00|| |
|10/8/2012||Fmr Llc||Insider||Sell||19,305||$13.02||$251,351.10|| |
Headline Trends for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Loading headlines, please wait.
Ironwood Pharmaceuticals (IRWD) Chart for Monday, October, 23, 2017